Accelerating Digital Health Solutions to Improve Outcomes for Patients with Chronic Diseases
AstraZeneca is collaborating with Massachusetts General Hospital to leverage robust data and clinical best practices in order to create digital health solutions that address today’s most urgent healthcare challenges. Catalyzed by the COVID-19 pandemic and a shared mission to improve care for patients with chronic illness, this novel partnership is focused on creating and clinically validating patient-centric digital health solutions and establishing a new standard of care for chronic illness management outside of a clinical setting.
This work is being led by CIDH and utilizes AstraZeneca’s new AMAZE™ disease management platform in studies for heart failure and asthma management. These first two studies pilot AMAZE in a real-world setting with the goals of improving patient engagement, care-team communication and clinical outcomes while reducing healthcare costs.
Through remote monitoring, AMAZE identifies at-risk patients and delivers insights to the clinical care team at the point of care to improve the management of complex patient populations. The digital platform, including a patient app and clinician dashboard, is intended to speed up adoption of evidence-based clinical practice with the aim of continuously improving the standard of patient care and healthcare efficiency.
Following the successful conclusion of the heart failure and asthma studies, AstraZeneca and Mass General plan to expand the use of AMAZE across multiple chronic disease areas, reaching patients throughout the Mass General Brigham system, and beyond.
Leveraging Lessons Learned During COVID-19 to Improve the Future of Virtual Care Management
CarePassport, a leading patient engagement developer, and BioIntellisense, a continuous health monitoring and clinical intelligence company, have extended their collaboration with Mass General Hospital and CIDH to leverage learnings from a COVID-19 pilot study, to focus on improving the future of virtual care management and bring next-generation solutions to the forefront.
Moving forward, this collaboration will design the technology platform to empower providers with tools to accurately track population health data across all specialties, improve overall patient outcomes, and enable patients to become more directly involved with their own care. Additional work will focus on technical advances in preventative and coordinated care, as well as the development of specialty products for critical diagnostics or diseases. Projects will include development of a pediatric app to help parents track their children’s health and quickly and securely relay important health information to their providers, and an app to better manage patients with Atrial Fibrillation (AFib), streamlining access to a patient’s health data from different wearables and third-party apps from a single login.
Combining the CarePassport platform and BioIntellisense BioButton, there is further potential to create tools for disease tracking and community wellness by healthcare facilities and government entities, as well as schools, businesses, and other services. Future research also will look at geolocation capabilities that can provide a pro-active view into real-time population data, decision support and real-time monitoring abilities.
Validating and Piloting Emerging Products in a Clinical Setting to Identify New Scientific Approaches to Pain Management
Fern Health, a digital health company pioneering virtual musculoskeletal pain programs and pain neuroscience education through employers, is collaborating with Massachusetts General Hospital and CIDH to validate emerging Fern Health product lines, pilot new products in a clinical setting, and investigate new scientific approaches to pain management.
Fern Health’s current product suite, which includes an evidence-based, digitally delivered musculoskeletal (MSK) pain management program, was originally developed with experts from Mass General, in consultation with their clinical collaborators at Spaulding Rehabilitation Network. Fern’s biopsychosocial pain management solution was validated with the clinical rigor of MGH’s renowned hospital-based research enterprise.